Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 235 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oral antivirals Clear all
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 8, 2026, 10:36 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mouth Rinses for Inactivation of COVID-19

NCT04584684
View directory record Official record
Conditions
Covid19, Coronavirus Infection, SARS-CoV-2 Infection
Interventions
0.9% w/v NaCL Saline, 1.5% w/v Hydrogen Peroxide, 0.12% Chlorohexidine Gluconate, 27% Ethanol plus essential oils, 0.5% w/v Povidone-iodide, 0.075% Cetylpyridinium Chloride
Other · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 8, 2026, 10:36 PM EDT
Active, not recruiting Phase 3 Interventional

Reducing Vertical Transmission of Hepatitis B in Africa

NCT04704024
View directory record Official record
Conditions
Hepatitis B Infection
Interventions
Tenofovir Disoproxil Fumarate, Lamivudine Oral Solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

NCT02743897
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Zepatier, Mavyret
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

NCT02536313
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU

NCT00000654
View directory record Official record
Conditions
Herpes Simplex, HIV Infections, Hepatitis B
Interventions
Fialuridine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 8, 2026, 10:36 PM EDT
Terminated Phase 1 Interventional

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

NCT05679388
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
Interventions
Relugolix Pill, Ritonavir, Itraconazole
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 8, 2026, 10:36 PM EDT
Withdrawn Phase 2 Interventional

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Daratumumab in STK11 Mutated NSCLC

NCT05807048
View directory record Official record
Conditions
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
Interventions
Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication, Post-Intervention Medication
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 8, 2026, 10:36 PM EDT
Terminated Phase 2 Interventional

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

NCT00040144
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ACH126, 433
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 8, 2026, 10:36 PM EDT
Suspended Phase 4 Interventional

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

NCT04334967
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV, 2019 Novel Coronavirus
Interventions
Hydroxychloroquine, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Providence Health & Services
Other
Eligibility
45 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 8, 2026, 10:36 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT01923311
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
EVG, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

NCT02098616
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
Drug
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 8, 2026, 10:36 PM EDT
Recruiting No phase listed Observational

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

NCT04979728
View directory record Official record
Conditions
HIV Treatment, HIV Prevention
Interventions
At Home Self-Collections
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 8, 2026, 10:36 PM EDT
Terminated Early Phase 1 Interventional

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

NCT03585725
View directory record Official record
Conditions
Follicular Lymphoma, Mantle Cell Lymphoma
Interventions
Ribavirin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

NCT02639247
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 8, 2026, 10:36 PM EDT
Completed No phase listed Observational

Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B

NCT01581554
View directory record Official record
Conditions
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 8, 2026, 10:36 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318
View directory record Official record
Conditions
Influenza
Interventions
Placebo for VNT-101, VNT-101
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

NCT00046332
View directory record Official record
Conditions
HIV Infections
Interventions
GW810781
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 8, 2026, 10:36 PM EDT
Terminated No phase listed Observational

Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment

NCT01715987
View directory record Official record
Conditions
Hepatitis B
Interventions
Tenofovir Disoproxil Fumarate, Entecavir
Drug
Lead sponsor
New Discovery LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 8, 2026, 10:36 PM EDT
Not listed Phase 2 Interventional

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

NCT00299897
View directory record Official record
Conditions
HIV Infections, Human Immunodeficiency Virus
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2006 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influenza Antiviral DAS-181-F04 in Healthy Adults

NCT01651494
View directory record Official record
Conditions
Influenza
Interventions
DAS181, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 8, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

NCT03739866
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Lenacapavir, Placebo, B/F/TAF, TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 8, 2026, 10:36 PM EDT